Using cryotherapy to prevent eyebrow and eyelash loss in breast cancer patients undergoing chemotherapy
Effect of Cryotherapy in the Prevention of Alopecia in Eyebrows and Eyelashes in Breast Cancer Patients Treated With Anthracyclines and Taxanes
This study is testing whether cryotherapy can help breast cancer patients keep their eyebrows and eyelashes while they undergo chemotherapy.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 120 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | University of Salamanca Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 2 sites (Santander, Cantabria and 1 other locations) |
| Trial ID | NCT06955702 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of targeted cryotherapy in preventing madarosis, or loss of eyebrows and eyelashes, in breast cancer patients receiving anthracycline- and taxane-based chemotherapy. Patients will undergo cryotherapy sessions before and after chemotherapy infusions, with hair retention measured at multiple timepoints using photogrammetric analysis. Additionally, the study aims to assess the impact of this intervention on patients' quality of life through validated questionnaires. The research will be conducted at two hospitals in Spain, with a total of 120 participants expected to enroll.
Who should consider this trial
Good fit: Ideal candidates are women over 18 years old, newly diagnosed with breast cancer, and scheduled to receive specific chemotherapy treatments.
Not a fit: Patients with recurrent breast cancer or those who have previously undergone chemotherapy or hormone therapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve the quality of life for breast cancer patients by preserving their eyebrows and eyelashes during chemotherapy.
How similar studies have performed: While scalp cryotherapy has shown success in preventing hair loss, the specific application of cryotherapy for preventing madarosis is less established and represents a novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Female participants aged ≥18 years * Newly diagnosed breast cancer (any stage) * Scheduled to receive anthracycline- and/or taxane-based chemotherapy as first-line systemic treatment * No prior history of antineoplastic treatment * Willing and able to provide written informed consent Exclusion Criteria: * Patients with recurrent disease who have received prior hormone therapy, chemotherapy, and/or immunotherapy * Presence of alopecia prior to the initiation of cancer treatment * History of cerebral radiotherapy
Where this trial is running
Santander, Cantabria and 1 other locations
- Hospital Marqués de Valdecilla — Santander, Cantabria, Spain (Recruiting)
- Hospital Universitario de Salamanca — Salamanca, Salamanca, Spain (Recruiting)
Study contacts
- Principal investigator: Marta González Fernández-Conde — Universidad Salamanca
- Study coordinator: Marta González Fernández-Conde, PhD Nursing
- Email: martagfc@usal.es
- Phone: 661544179
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.